8-K: Greenwave Technology Solutions Secures $4 Million in Registered Direct Offering and Private Placement
Capital Raise Announcement
Greenwave Technology Solutions has entered into a securities purchase agreement to sell shares and warrants for gross proceeds of approximately $4 million.
Summary
- Greenwave Technology Solutions, Inc. has agreed to sell 7,544,323 shares of common stock and accompanying warrants in a registered direct offering and concurrent private placement.
- The gross proceeds from the offering are expected to be approximately $4 million, before deducting fees and expenses.
- The purchase price per share and accompanying warrant is $0.5302.
- The warrants will be exercisable upon stockholder approval and have an exercise price of $0.5302 per share, expiring five years from the approval date.
- The company intends to use the net proceeds for debt satisfaction and working capital.
- The offering is expected to close on or about January 14, 2025.
- Dawson James Securities, Inc. is acting as the placement agent and will receive a 6% cash fee and warrants to purchase 754,432 shares at $0.66275 per share.
- The company also entered into exchange agreements with certain warrant holders to exchange warrants for 5,327,401 shares of common stock.
- Existing warrants were amended to reduce the exercise price to $1.50 per share and increase the number of shares issuable by 250%.
Sentiment
Score: 4
Explanation: The document indicates a necessary capital raise, but the terms are not particularly favorable for existing shareholders due to potential dilution and fees. The company is taking steps to improve its financial position, but the overall sentiment is neutral to slightly negative.
Positives
- The capital raise will provide funds for debt satisfaction and working capital.
- The reduction in exercise price of existing warrants may encourage their exercise.
- The company has secured a placement agent to assist with the offering.
Negatives
- The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders.
- The warrants have a cashless exercise option, which could further dilute shareholders if exercised.
- The company is paying a 6% cash fee to the placement agent, which reduces the net proceeds.
Risks
- The company needs stockholder approval for the issuance of the warrants and warrant shares.
- The company needs to file a registration statement for the resale of the warrant shares.
- The company may redeem the warrants if the stock price exceeds 200% of the exercise price for 20 consecutive trading days.
- The company is subject to potential penalties for failing to deliver shares on time after exercise of warrants.
Future Outlook
The company intends to use the net proceeds from the offering for debt satisfaction and working capital purposes. The company will also seek stockholder approval for the issuance of the warrants and warrant shares and file a registration statement for the resale of the warrant shares.
Industry Context
This announcement reflects a common strategy for small-cap companies to raise capital through direct offerings and private placements. The use of warrants is a typical incentive for investors in such offerings. The amendment of existing warrants is a way to potentially increase the number of shares available for trading and reduce the risk of dilution.
Comparison to Industry Standards
- The use of registered direct offerings and concurrent private placements is a common method for small-cap companies to raise capital.
- The terms of the warrants, including the exercise price and expiration date, are within the typical range for such offerings.
- The placement agent fee of 6% is also within the typical range for such transactions.
- The amendment of existing warrants to reduce the exercise price and increase the number of shares is a strategy to encourage warrant holders to exercise their options, which can provide additional capital to the company.
- Comparable companies in the micro-cap space often use similar financing methods, including companies like those listed on the OTC markets or smaller exchanges.
Stakeholder Impact
- Existing shareholders will experience dilution due to the issuance of new shares.
- New investors will have the opportunity to participate in the company's growth.
- The company's creditors may benefit from the debt satisfaction.
- Employees may benefit from the improved financial stability of the company.
Next Steps
- The company will close the offering on or about January 14, 2025.
- The company will seek stockholder approval for the issuance of the warrants and warrant shares.
- The company will file a registration statement for the resale of the warrant shares.
- The company will use the net proceeds for debt satisfaction and working capital.
Key Dates
| Date | Description |
|---|---|
| 2023-04-28 | Effective date of the company's shelf registration statement on Form S-3. |
| 2024-03-18 | Date of issuance of the March Warrants. |
| 2024-04-22 | Date of issuance of the April Warrants. |
| 2024-05-16 | Date of issuance of the May Warrants. |
| 2024-06-12 | Date of issuance of the June Warrants. |
| 2025-01-10 | Date of the securities purchase agreement, exchange agreements, and warrant amendment. |
| 2025-01-13 | Date of legal opinion and expected filing of prospectus supplement. |
| 2025-01-14 | Expected closing date of the offering. |
| 2025-06-15 | Target date for special meeting of stockholders to approve the issuance of warrants and warrant shares. |
Keywords
registered direct offering, private placement, common stock, warrants, capital raise, stockholder approval, exercise price, placement agent, dilution, debt satisfaction, working capital
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.